UBS Raises PT and Estimates on Dr Pepper Snapple (DPS); Thesis Is Still Limited Upside
Tweet
Share
E-mailGet Alerts DPS Hot Sheet
Price: $123.66 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
UBS reiterates a 'Neutral' on Dr Pepper Snapple (NYSE: DPS) price target of $45.00 (from $43.00).
Analyst, Kaumil S. Gajrawala, said, "We are increasing our 2012 EPS estimate to $2.95 (from $2.93), to reflect: 1) the $0.03 EPS beat in 2Q, and 2) an improving commodity cost outlook (flat in 3Q, up 3% in 4Q) offset by a higher tax rate in the back half. We are forecasting flat volumes with 3% pricing. COGS inflation is expected to be +2%, resulting in slight gross margin expansion." (FY13 from $3.28 to $3.32)
Keeps Neutral rating as management continues making the right moves/strategy, however, still negative n-t volumes and increasing competitive marketplace.
For an analyst ratings summary and ratings history on Dr Pepper Snapple click here. For more ratings news on Dr Pepper Snapple click here.
Shares of Dr Pepper Snapple closed at $44.66 yesterday.
Analyst, Kaumil S. Gajrawala, said, "We are increasing our 2012 EPS estimate to $2.95 (from $2.93), to reflect: 1) the $0.03 EPS beat in 2Q, and 2) an improving commodity cost outlook (flat in 3Q, up 3% in 4Q) offset by a higher tax rate in the back half. We are forecasting flat volumes with 3% pricing. COGS inflation is expected to be +2%, resulting in slight gross margin expansion." (FY13 from $3.28 to $3.32)
Keeps Neutral rating as management continues making the right moves/strategy, however, still negative n-t volumes and increasing competitive marketplace.
For an analyst ratings summary and ratings history on Dr Pepper Snapple click here. For more ratings news on Dr Pepper Snapple click here.
Shares of Dr Pepper Snapple closed at $44.66 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Okta, Inc (OKTA) PT Raised to $170 at Cantor Fitzgerald Ahead of Q2 Results
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
